by Madaline Spencer | Feb 14, 2025
Carsten Utoft Niemann, MD, PhD, Copenhagen University Hospital, discusses results from the GLOW clinical trial in chronic lymphocytic leukemia (CLL). CLL is a rare cancer of the lymphocytes. Early signs and symptoms may include swollen lymph nodes,...
by Madaline Spencer | Feb 13, 2025
Deeksha Vishwamitra, Janssen Research & Development, discusses an analysis of the TRIMM-2 clinical trial evaluating combination therapy tal-DP in patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm...
by Madaline Spencer | Feb 12, 2025
The U.S. Food and Drug Administration has approved Gomekli (mirdametinib) for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas. Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin,...
by Madaline Spencer | Feb 12, 2025
Anita D’Souza, MD, Medical College of Wisconsin, discusses results from the MajesTEC-2 and TRIMM-2 clinical trials for combination therapy teclistamab + daratumumab + pomalidomide (tec-DP) in patients with multiple myeloma. Multiple myeloma is a bone...
by Madaline Spencer | Feb 11, 2025
Arturo Molina, MD, Protagonist Therapeutics, discusses results from the phase 2 REVIVE clinical trial testing rusfertide in patients with polycythemia vera (PV). PV is a myeloproliferative disorder characterized by an elevated absolute red blood cell...
